Cwm LLC Buys 287 Shares of Qiagen (NYSE:QGEN)

Cwm LLC grew its stake in shares of Qiagen (NYSE:QGEN) by 11.5% in the third quarter, HoldingsChannel.com reports. The fund owned 2,792 shares of the company’s stock after acquiring an additional 287 shares during the quarter. Cwm LLC’s holdings in Qiagen were worth $127,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC lifted its position in shares of Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the last quarter. Toronto Dominion Bank bought a new stake in shares of Qiagen during the 2nd quarter worth $27,000. Park Place Capital Corp bought a new stake in shares of Qiagen during the 1st quarter worth $36,000. Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after buying an additional 243 shares during the last quarter. Finally, Headlands Technologies LLC lifted its position in shares of Qiagen by 396.6% during the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after buying an additional 2,189 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on QGEN shares. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research report on Thursday, October 17th. Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a report on Thursday, June 27th. Finally, Robert W. Baird upped their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Qiagen has an average rating of “Moderate Buy” and a consensus price target of $50.12.

Qiagen Trading Down 1.3 %

Shares of QGEN stock opened at $41.59 on Friday. The stock has a 50-day moving average of $44.78 and a 200-day moving average of $43.53. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.44. The stock has a market cap of $9.49 billion, a price-to-earnings ratio of 138.39, a PEG ratio of 3.22 and a beta of 0.39. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The business had revenue of $496.00 million during the quarter, compared to analysts’ expectations of $495.45 million. During the same quarter last year, the firm posted $0.53 earnings per share. The firm’s revenue was down .2% on a year-over-year basis. On average, equities research analysts forecast that Qiagen will post 2.15 earnings per share for the current year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.